Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

FXFM244

Small molecule · Inhibitor · developed by Vyne Therapeutics

Early Phase 1 Most advanced trial
1 Registered trials

What is FXFM244?

FXFM244 is a topical minocycline foam formulation. Minocycline is a tetracycline antibiotic that inhibits bacterial protein synthesis. It is being studied for confluent and reticulated papillomatosis (CARP).

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Mechanism
Inhibitor
Pathways
bacterial protein synthesis
Therapy area
Dermatology
Developer
Vyne Therapeutics Inc.
In trials of
DERM
FDA status
Investigational, not approved in the US. Most advanced trial: Early Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07462702 Early Phase 1 Confluent and Reticulated Papillomatosis (CARP) Not yet recruiting DERM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Confluent and Reticulated Papillomatosis (CARP)

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.